National Health (Take Home Naloxone) Special Arrangement 2019
6Definitions
Start here
Get a plain-English read of 6
Turn the raw legal text into a practical explanation grounded in National Health (Take Home Naloxone) Special Arrangement 2019.
6 Definitions
Note: A number of expressions used in this instrument are defined in the Act, including the following:
(a) hospital;
(b) premises;
(c) Secretary.
In this instrument:
Act means the National Health Act 1953.
approved ex‑manufacturer price of a listed brand of a pharmaceutical item has the same meaning as in Part VII of the Act.
approved hospital authority has the same meaning as in Part VII of the Act.
approved medical practitioner has the same meaning as in Part VII of the Act.
approved pharmacist has the same meaning as in Part VII of the Act.
approved supplier has the same meaning as in Part VII of the Act.
authorised alternative supplier means a person or organisation:
(a) that has premises in a jurisdiction; and
(b) that is authorised (however described) by an authority of the jurisdiction for the purposes of supplying designated pharmaceutical benefits in accordance with this instrument; and
(c) in relation to which the authority has given the Secretary a written notice stating:
(i) that the person or organisation is so authorised; and
(ii) the name and contact details of the person or organisation.
day admitted patient: a person is a day admitted patient of a hospital on a day if, on that day, the person:
(a) is admitted to the hospital (other than through the hospital’s emergency department); and
(b) receives treatment; and
(c) is discharged from the hospital;
in accordance with a pre‑existing plan for the person’s treatment.
designated person means:
(a) a person who is at risk of an opioid overdose; or
(b) a person who is likely to be able to assist such a person.
designated pharmaceutical benefit means a pharmaceutical benefit mentioned in Schedule 1.
excluded approved supplier means an approved supplier in a jurisdiction in relation to which there is in force a notice given by an authority of the jurisdiction to the Secretary and the supplier to the effect that the authority wants the supplier not to be able to supply designated pharmaceutical benefits in accordance with this instrument.